Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Valneva SE

$5.34 -2.65% NASDAQ: VALN · 15-min delayed
  • Public · NASDAQ: VALN
  • 674 employees
  • Founded 2013
$519.6MMarket cap
674Employees
VALNNASDAQ
2021IPO

About Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Market cap
$519.6M
NASDAQ: VALN
$5.34 -2.65%

15-minute delayed · data by Polygon.io

Past year

$5.17 $12.20

52-week range

Market cap
$519.6M
Shares outstanding
97.3M
Open
Day range
Prev close
Volume
IPO date
May 6, 2021

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

  • Trading 56% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Valneva SE.

Write a review
Newsroom

News about Valneva SE

News & sentiment via Polygon.io

Explore

Similar companies

Browse all →